Paroxysmal Atrial Fibrillation

Cardiovascular
3
Pipeline Programs
5
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Rhythm Pharmaceuticals
2 programs
1
1
Arctic Front Advance Cardiac CryoAblation systemPhase 41 trial
Arctic Front® Cryoablation CatheterPhase 31 trial
Active Trials
NCT00523978Completed245Est. Jul 2011
NCT01645917Completed21Est. Nov 2013
Ionis Pharmaceuticals
1 program
1
ISIS CRP RxPhase 21 trial
Active Trials
NCT01710852Completed7Est. Apr 2014
Abbott
AbbottABBOTT PARK, IL
5 programs
A specific electrophysiology mapping protocol is applicable with the GRID catheter.N/A1 trial
Electrophysiology studyN/A1 trial
TactiCath Quartz treatmentN/A1 trial
TactiCath SEN/A1 trial
TactiFlex SEN/A1 trial
Active Trials
NCT03882021Completed300Est. Jan 2022
NCT02131337Completed45Est. Oct 2011
NCT02310100Completed178Est. Sep 2021
+2 more trials
Kardium
KardiumBC - Burnaby
1 program
Globe Pulsed Field SystemN/A1 trial
Active Trials
NCT05462145Active Not RecruitingEst. Sep 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Rhythm PharmaceuticalsArctic Front Advance Cardiac CryoAblation system
Rhythm PharmaceuticalsArctic Front® Cryoablation Catheter
Ionis PharmaceuticalsISIS CRP Rx
KardiumGlobe Pulsed Field System
AbbottTactiFlex SE
AbbottA specific electrophysiology mapping protocol is applicable with the GRID catheter.
AbbottTactiCath SE
AbbottTactiCath Quartz treatment
AbbottElectrophysiology study

Clinical Trials (9)

Total enrollment: 1,307 patients across 9 trials

NCT01645917Rhythm PharmaceuticalsArctic Front Advance Cardiac CryoAblation system

Durability of Pulmonary Vein Isolation Following Cryoablation for Treatment of Paroxysmal Atrial Fibrillation

Start: Aug 2012Est. completion: Nov 201321 patients
Phase 4Completed
NCT00523978Rhythm PharmaceuticalsArctic Front® Cryoablation Catheter

A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation

Start: Oct 2006Est. completion: Jul 2011245 patients
Phase 3Completed

Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation

Start: Oct 2012Est. completion: Apr 20147 patients
Phase 2Completed
NCT05462145KardiumGlobe Pulsed Field System

Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation

Start: Mar 2023Est. completion: Sep 2026
N/AActive Not Recruiting
NCT04356040AbbottTactiFlex SE

TactiFlex Paroxysmal Atrial Fibrillation IDE Trial

Start: Jun 2020Est. completion: Jul 2022355 patients
N/ACompleted
NCT03882021AbbottA specific electrophysiology mapping protocol is applicable with the GRID catheter.

High-Density (HD) Wave Mapping in Subjects With Atrial Fibrillation as a Predictor of Recurrence After a Single Ablation Procedure Using a PVI-Only Strategy

Start: Aug 2019Est. completion: Jan 2022300 patients
N/ACompleted
NCT03354663AbbottTactiCath SE

TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation

Start: Dec 2017Est. completion: Oct 2019156 patients
N/ACompleted
NCT02310100AbbottTactiCath Quartz treatment

TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Post Approval Study

Start: Jan 2015Est. completion: Sep 2021178 patients
N/ACompleted
NCT02131337AbbottElectrophysiology study

TactiCath® Prospective Effectiveness Pilot Study

Start: Dec 2010Est. completion: Oct 201145 patients
N/ACompleted

Related Jobs in Cardiovascular

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space